Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Auto stocks lead the rally
Fri, 28 Sep 11:30 am

Indian equity markets continues to trade strong over the last two hours of trade on back of heavy buying activity witnessed across industry heavyweights. Auto and metal stocks witnessed maximum buying interest.

The Sensex today is up by 263 points, while the NSE-Nifty today is up by 77 points. BSE Mid Cap index and the BSE Small Cap index are up by 1.33% and 1.05%. The rupee is trading at 52.70 to the US dollar.

Energy stocks are trading in the green led by Oil and Natural Gas Corporation Ltd. (ONGC) and Cairn India. According to a leading financial daily, ONGC Teri Biotech Limited (OTBL), the joint venture between state-run explorer Oil and Natural Gas Corporation (ONGC) and The Energy and Research Institute (Teri), is planning to bid for Rs 150 bn desert oil slick clean-up contract in Kuwait. The Kuwait Oil Company has engaged a project monitoring consultant to prepare the tender specifications. The specifications could be ready by January 2013. The contract is to clear the oil slick created in the Gulf war following Iraq's invasion of Kuwait in 1990. The contract being a USD $3 bn project, OTBL might have to use ONGC's balance sheet to be eligible to bid for the project. ONGC has a 49.9% stake in OTBL, while Teri's stake is 48%.

Pharma stocks are trading strong led by Cadila Healthcare and Aurobindo Pharma. As per a leading daily, the Group of Ministers (GoM) in charge of formulating the New Pharmaceutical Pricing Policy have proposed to bring prices of around 348 drugs under government control. At present the government controls 74 drugs and their formulations through the National Pharmaceutical Pricing Authority. The GoM will send their recommendations to the cabinet for approval. This is aimed with the objective to bring drugs in National List of Essential Medicines (NLEM). The cost based formula has been discarded and the ceiling price will be calculated by using the weighted average price (WAP) of brands with over 1% market share by volume. However, the pharmaceutical industry is not happy with this decision as it may result in loss of revenues for them in the short term.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Auto stocks lead the rally". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.